PMV Pharmaceuticals (PMVP)
(Delayed Data from NSDQ)
$1.55 USD
+0.02 (1.31%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $1.55 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
PMV Pharmaceuticals, Inc. (PMVP) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$5.75 | $7.00 | $5.00 | 275.82% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for PMV Pharmaceuticals, Inc. comes to $5.75. The forecasts range from a low of $5.00 to a high of $7.00. The average price target represents an increase of 275.82% from the last closing price of $1.53.
Analyst Price Targets (4 )
Broker Rating
PMV Pharmaceuticals, Inc. currently has an average brokerage recommendation (ABR) of 1.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.33 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, five are Strong Buy, representing 83.33% of all recommendations. A month ago, Strong Buy represented 83.33%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/PMVP.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.33 | 1.33 | 1.33 | 1.33 | 1.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/20/2024 | H.C. Wainwright & Co. | Robert Burns | Strong Buy | Strong Buy |
6/17/2024 | LadenburgThalmann | Aydin Huseynov | Strong Buy | Strong Buy |
5/13/2024 | Craig-Hallum | Albert Lowe | Not Available | Strong Buy |
5/9/2024 | Not Identified | Not Identified | Hold | Hold |
4/12/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Yaron Werber | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.33 |
ABR (Last week) | 1.33 |
# of Recs in ABR | 6 |
Average Target Price | $5.75 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 96 of 253 |
Current Quarter EPS Est: | -0.36 |